FEHB Blue Cross Blue Shield (empleados federales) · Indicación de riesgo cardiovascular (Wegovy SELECT) · Versión completa en inglés: /pa-letter/fehb-bcbs--cv-indication/
Carta de PA para FEHB Blue Cross Blue Shield (empleados federales): Indicación de riesgo cardiovascular (Wegovy SELECT).
Plantilla defensible de carta para Wegovy (semaglutide 2.4 mg). FDA expanded Wegovy's label in March 2024 to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This is a Medicare-eligible indication.
La carta misma está en inglés porque el revisor del plan la lee en inglés. La envuelve y la firma su clínico.
Cita de política: Blue Cross and Blue Shield Service Benefit Plan, Federal Employee Program, GLP-1 PA Criteria.
Nota del plan: FEP BCBS covers Wegovy and Zepbound for obesity at BMI greater than or equal to 30 (or 27 with comorbidity) with documented dietary intervention. The FEP formulary is generally more generous than commercial Anthem for anti-obesity drugs because federal coverage mandates are statutorily different. PBM is CVS Caremark.
Nota del plan: FEP BCBS covers Wegovy and Zepbound for obesity at BMI greater than or equal to 30 (or 27 with comorbidity) with documented dietary intervention. The FEP formulary is generally more generous than commercial Anthem for anti-obesity drugs because federal coverage mandates are statutorily different. PBM is CVS Caremark.
Lo que CVS Caremark realmente requiere
FEHB Blue Cross Blue Shield (empleados federales) contrata la administración del beneficio de farmacia a CVS Caremark, que adjudica esta PA. Los criterios siguientes provienen de la política clínica del PBM publicada públicamente. Cumpla cada uno antes de enviar.
- BMI greater than or equal to 30, OR BMI greater than or equal to 27 with at least one weight-related comorbidity (T2D, hypertension, dyslipidemia, OSA)
- Documented six-month lifestyle intervention or prior anti-obesity medication trial
- Step therapy through phentermine or orlistat (or documented contraindication / intolerance)
- Treatment plan including continued lifestyle counseling and 5 percent weight-loss target at 6 months
- Reauthorization requires documented adherence and ≥5 percent weight loss from baseline at 12 months
La carta (copiar y editar)
Copie el cuerpo a continuación y péguelo en el portal de su clínico o procesador de textos. Reemplace cada marcador de posición entre [CORCHETES] con datos específicos del paciente antes de enviar. La carta es de su clínico al plan, firmada por su clínico.
[Today's date] FEHB Blue Cross Blue Shield (Federal Employee Program) Prior Authorization Department Submitted via: CVS Caremark Federal Employee Program portal or fax 1-855-330-1716 Re: Prior Authorization Request, Wegovy (semaglutide 2.4 mg) Patient: [Patient full name] Member ID: [Plan member ID] Date of birth: [Patient DOB] Group number: [Group number if applicable] Prescriber: [Prescriber full name, NPI, DEA] Prescriber contact: [Phone, fax, email] To the FEHB Blue Cross Blue Shield (Federal Employee Program) Prior Authorization Reviewer, I am the treating clinician for [Patient name]. I am writing to request prior authorization for Wegovy (semaglutide 2.4 mg) for treatment of Cardiovascular risk indication (Wegovy SELECT) (ICD-10: I25.10, I63.9, I50.9, E66.01). Clinical justification FDA approved Wegovy (semaglutide 2.4 mg) for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight in March 2024, based on the SELECT trial. SELECT enrolled 17,604 adults with established cardiovascular disease and BMI greater than or equal to 27 without diabetes. Over a median 39.8 months of follow-up, Wegovy reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke by 20 percent versus placebo (hazard ratio 0.80; published New England Journal of Medicine, November 2023). This is now a Medicare Part D-eligible indication independent of any obesity or T2D criteria. Patient-specific findings - [Insert current measurements: weight, height, BMI, blood pressure] - [Insert relevant lab values with dates: A1c, lipid panel, kidney function] - [Insert documentation of comorbidities with ICD-10] - [Insert documentation of prior treatment history, including any prior GLP-1 trials, anti-obesity medication trials or lifestyle intervention] Criteria met per FEHB Blue Cross Blue Shield (Federal Employee Program) policy This request meets the criteria set out in Blue Cross and Blue Shield Service Benefit Plan, Federal Employee Program, GLP-1 PA Criteria: - Established cardiovascular disease: prior MI (I21.x history), prior stroke or TIA (I63.x or G45.x) or established coronary artery disease (I25.x) - BMI greater than or equal to 27 - No active T2D diagnosis required for this pathway (this is the obesity-or-overweight SELECT criteria, not the T2D pathway) - Cardiology or primary care attestation that patient is at elevated cardiovascular risk - Most recent imaging or cardiac event documentation Supporting evidence The clinical case for Wegovy (semaglutide 2.4 mg) in this indication is supported by the following registration trials and outcomes data: - SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), Lincoff et al., NEJM 2023 Plan-specific note FEP BCBS covers Wegovy and Zepbound for obesity at BMI greater than or equal to 30 (or 27 with comorbidity) with documented dietary intervention. The FEP formulary is generally more generous than commercial Anthem for anti-obesity drugs because federal coverage mandates are statutorily different. PBM is CVS Caremark. Requested action I am requesting prior authorization for Wegovy (semaglutide 2.4 mg) at the [insert starting dose] starting dose, with planned titration per FDA labeling. I am also requesting that this authorization be granted for a continuous 12-month period subject to documented clinical response, per standard formulary practice. If additional information is required, please contact me directly at [Prescriber phone] or [Prescriber email]. I am available to discuss this case with your medical director if helpful. Thank you for your attention to this request. Sincerely, [Prescriber full signature] [Prescriber printed name, credentials] [Prescriber NPI] [Practice name and address] Attachments: - Current vital signs and BMI calculation - Most recent relevant labs - Documentation of comorbidities - Documentation of prior treatment trials - Sleep study report (if OSA indication) - Cardiac history documentation (if CV indication)
Aviso legal
Plantillas educativas únicamente. No constituyen asesoramiento legal ni médico. Las cartas deben ser firmadas por el clínico tratante (MD, DO, NP, PA) con autoridad de prescripción. Cada plan cambia los criterios trimestralmente. Verifique con el boletín de política de PA más reciente de su plan antes de enviar. No invente hallazgos clínicos. No altere la firma de un clínico.
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.